VDAC1 and Parkinson disease: Several VDAC1-targeting compounds, such as VBIT-4, VBIT-12, resveratrol, and olesoxime, have demonstrated neuroprotective effects by restoring mitochondrial function, reducing ROS production, and inhibiting pathogenic protein interactions in preclinical models of AD, PD, and ALS.